Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review
Open accessThe DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index; 145 of the 244 sources its claims cite were checked for support.
Abstract
Background: Berberine, an isoquinoline alkaloid present in Berberis spp., Coptis chinensis and Hydrastis canadensis, is among the most widely consumed metabolic-health supplements, popularized as “nature’s Ozempic”. Concurrent, often undisclosed use with prescription drugs is common in older adults, yet berberine is far from inert. Objective: To synthesize the evidence on berberine as a perpetrator of supplement–drug interactions, propose a four-axis mechanistic taxonomy, with product quality treated separately as a modifier of exposure rather than as a mechanism, and derive a clinically actionable risk-stratification framework. Methods: Structured narrative review, prepared per the SANRA quality criteria; PubMed/MEDLINE, Scopus, Web of Science and Embase were searched up to May 2026. Results: Despite very low systemic exposure (oral bioavailability 0.68% in rats; low ng/mL plasma concentrations in humans), high luminal, enterocytic and hepatic concentrations generate interaction liability, documented in humans for a few pairs and mechanistic for most, along four mechanistic axes: inhibition, and transcriptional induction, of CYP3A4, with CYP2D6/CYP2C9 inhibition that is quasi-irreversible through a metabolite-intermediate complex; transporter modulation (P-glycoprotein, OCT1/OCT2, and MATE1); pharmacodynamic additivity (hypoglycemia, hypotension, and QT prolongation); and microbiome- and gut-barrier-mediated effects, the last of these being a candidate axis rather than a demonstrated one. Product-quality variability is treated separately, as a modifier of exposure. The clinical anchor is increased cyclosporine exposure in renal-transplant recipients (AUC +34.5%; trough 29.3% above control). These elements are integrated into a three-tier risk-stratification framework that combines perpetrator potency, victim-drug vulnerability, and patient vulnerability, with each tier being linked to a defined pharmacy action. Conclusions: In patients on multiple medications, and particularly when berberine is co-administered with drugs of narrow therapeutic index, it should be managed as an active pharmacological perpetrator rather than as an inert supplement. Unstandardized product quality and an unsettled European regulatory framework, under which national limits differ by more than an order of magnitude, further widen the uncertainty around the dose actually delivered. Berberine use should therefore be elicited routinely at medication reconciliation and stratified by mechanism, by victim-drug vulnerability, and by patient risk, with particular attention to metabolic self-medication in the GLP-1 era.
Overview
CoChat Summary
TL;DR
Berberine is an active pharmacological perpetrator of supplement–drug interactions despite very low systemic bioavailability, acting through CYP inhibition/induction, transporter modulation, pharmacodynamic additivity, and a candidate microbiome axis. The review proposes a four-axis mechanistic taxonomy plus product-quality exposure modifier and a three-tier risk-stratification framework, anchored clinically by increased cyclosporine exposure in renal-transplant recipients.
Key findings
- Berberine oral bioavailability is very low (0.68% in rats; below a few percent in humans), with plasma concentrations of a few ng/mL (roughly 1–10 nM after 400–500 mg), but nominal upper-small-intestinal luminal concentration near 5 mM; in vitro potencies cluster at 1–45 µM, so luminal concentrations exceed that band by two to three orders of magnitude while plasma falls below it by two to four.
- The clinical anchor is cyclosporine: 12 days of berberine 0.2 g three times daily increased cyclosporine AUC by 34.5% and reduced apparent oral clearance by 40.4%; in a parallel controlled trial (n = 104), trough concentrations rose 88.9% from baseline in the berberine group versus 64.5% in the berberine-free group, with between-group differences at study end of 29.3% for trough concentration and 27.8% for concentration/dose ratio.
- Proposed mechanisms include quasi-irreversible CYP2D6 inhibition via a metabolite-intermediate complex, CYP3A4/CYP2C9 inhibition, PXR-mediated CYP3A4 induction, transporter modulation (P-gp, OCT1/OCT2/MATE1; OCT IC50s 18.8, 1.02, and 10.7 µM), pharmacodynamic additivity (hypoglycemia, hypotension, QT prolongation), and a candidate microbiome/gut-barrier axis; a 16-volunteer probe-cocktail study found goldenseal extract reduced metformin exposure while increasing midazolam AUC (geometric mean ratio 1.43; 90% CI 1.35–1.53).
- The risk-stratification framework combines perpetrator potency, victim-drug vulnerability (especially narrow therapeutic index), and patient vulnerability (age, renal/hepatic function, cardiac comorbidities, pregnancy); evidence grading gives only cyclosporine Grade A, with most pairs potential or mechanistic and Axis 4 having nothing above Grade D.
Methods
- Structured narrative review prepared per SANRA quality criteria; no meta-analysis was performed. PubMed/MEDLINE, Scopus, Web of Science Core Collection, and Embase were searched without date restriction up to May 2026, with targeted searches for cyclosporine, metformin, warfarin, and midazolam, plus manual reference screening.
- Included in vitro enzyme/transport studies, preclinical models, clinical pharmacokinetic/pharmacodynamic studies, case reports and series, systematic reviews, and regulatory documents; excluded works without interaction or mechanism data, unverifiable conference abstracts except relevant safety signals, and purely commercial literature. Data were extracted descriptively and synthesized thematically across four mechanistic axes and the exposure modifier.
- Evidence was graded A–E: Grade A controlled clinical study using the victim drug itself; Grade B human clinical study with probe substrates, enzyme-activity, or pharmacodynamic endpoints; Grade C in vivo preclinical; Grade D in vitro or mechanistic/PBPK; Grade E no direct data. Case reports were graded separately.
Limitations
- The paper states that as a narrative review it lacks an aggregated quantitative assessment and is more exposed to selection subjectivity than a registered systematic review; much mechanistic evidence comes from in vitro and preclinical studies in which berberine concentrations may exceed human systemic exposure; commercial product heterogeneity limits generalizability of effect-size estimates.
- The paper states that prospective clinical interaction studies are almost absent: across the field it identified one controlled study in patients (renal-transplant recipients receiving cyclosporine), one probe-cocktail study in healthy volunteers, and one human enzyme-phenotyping study; everything else is preclinical, in vitro, or observational. It also notes likely publication bias overstating frequency and size, case-report attribution problems, under-reporting to pharmacovigilance, and a translational gap in which local concentrations are calculated but not measured in humans and PBPK models are not validated against clinical data.
- Evident from the text and acknowledged by the authors: the patient-vulnerability dimension of the risk framework is expert interpretation because no study stratified a berberine interaction by age, renal/hepatic function, or cardiac comorbidity; the High risk row is anchored on Grade A evidence for cyclosporine alone, with other drugs placed there by mechanism and consequences rather than direct data; Axis 4 is a candidate mechanism, and no study has measured a co-administered drug’s disposition before and after berberine while characterizing the microbiota in the same subjects.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Site-of-interaction map and the bioavailability paradox. Despite low systemic bioavailability, berberine reaches concentrations orders of magnitude higher at the sites of absorption (intestinal lumen, enterocyte) and elimination (liver, kidney), where the majority of interactions occur [37,43,48]. Only the boxes numbered Axis 1 to Axis 4 are mechanistic axes of the taxonomy. The box labeled Exposure modifier-Product quality is deliberately left unnumbered: product identity, declared versus actual alkaloid content, and formulation are not a biological mechanism of interaction but a cross-cutting modifier that sets the perpetrator dose on which all four mechanistic axes operate (Section 2.2.5). It is drawn at the intestinal-lumen level because that is where the delivered dose first becomes relevant, and its position immediately below Axis 4 carries no hierarchical meaning. Panel ( A ) maps the successive compartments through which orally administered berberine passes-intestinal lumen, enterocyte, portal vein and liver, systemic circulation, and renal proximal tubule-and aligns each compartment with the mechanistic axis that operates at that site; the grey downward triangles indicate the direction of this transit and carry no quantitative meaning. Panel ( B ) compares, on a logarithmic scale, the concentrations attained in the intestinal lumen, at the gut wall and liver, and in systemic plasma; it is schematic and not drawn to scale. Original figure by the authors.](https://figures.cochat.ai/paper-figures/ae42ad7af7de44f3b19ad347d1fcaf45/berberine-drug-interactions-mechanisms-clinical-relevance-and-risk-figure-1.png)
Verification
Claims the paper makes
78 Valid · 8 Not valid · 35 Not checked · 38 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“yet berberine is far from inert”
- Also stated in: § 1. Introduction · plain
“The second is berberine’s pharmacology itself, which is far from inert [35,36].”
§ Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification—A Narrative Review > Abstract
What the sources say
- Supportedcites [35] Guo Y. Chen Y. Tan Z.R. Klaassen C.D. Zhou H.H. Repeated administration of berberine inhibits cytochromes P450 in humans Eur. J. Clin. Pharmacol. 2012 68 213 217 10.1007/s00228-011-1108-2 21870106 PMC4898966 source
The Conclusion reports that berberine inhibited CYP2D6, CYP3A4, and CYP2C9 and says drug interactions should be considered. That supports the broad claim that berberine is not inert. No page number is provided in our copy. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [36] Etheridge A.S. Black S.R. Patel P.R. So J. Mathews J.M. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents Planta Med. 2007 73 731 741 10.1055/s-2007-981550 17611934 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“with CYP2D6/CYP2C9 inhibition that is quasi-irreversible through a metabolite-intermediate complex”
- Also stated in: § 2.2. Taxonomy of Berberine’s Interaction Mechanisms · boosted
“CYP2D6 inhibition is quasi-irreversible in the strict pharmacological sense rather than simply long-lasting, and the primary source describes it as such: the effect develops in a time-, concentration-, and NADPH-dependent manner and is attributed to formation of a metabolite-intermediate complex (MIC) with the heme iron [59].”
§ Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification—A Narrative Review > Abstract
What the sources say
- Partly supportedcites [59] Kim H.G. Lee H.S. Jeon J.S. Choi Y.J. Choi Y.J. Yoo S.Y. Kim E.Y. Lee K. Park I. Na M. Quasi-Irreversible Inhibition of CYP2D6 by Berberine Pharmaceutics 2020 12 916 10.3390/pharmaceutics12100916 32987920 PMC7600264 sourceExperimental — accuracy not yet measured
Results §3.4 and the Discussion support quasi-irreversible CYP2D6 inhibition by berberine and link it to a possible metabolite-intermediate complex. But Results §3.1 explicitly says CYP2C9 was not markedly inhibited by berberine; the paper does not establish the claimed mechanism for CYP2C9. (LLM, conf=0.90)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2.2. Taxonomy of Berberine’s Interaction Mechanisms · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“transcriptional induction, of CYP3A4”
- Also stated in: § 2.2. Taxonomy of Berberine’s Interaction Mechanisms · plain
“Recent data show that berberine and its metabolite berberrubine can induce, in a concentration-dependent manner, the expression of CYP3A4 through activation of the nuclear pregnane X receptor (PXR) [75].”
§ Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification—A Narrative Review > Abstract
What the sources say
- Supportedcites [75] Xiao G.M. Lu T. Zhu D. Liu M.Y. Berberine and berberrubine promote the expression of CYP3A4 via enhancing the binding of nuclear receptor PXR BMC Pharmacol. Toxicol. 2025 26 187 10.1186/s40360-025-01026-7 41199315 PMC12593850 source
The Abstract Results report that berberine induced CYP3A4 mRNA expression, and the Abstract Conclusion links increased expression in HepG2 cells to PXR binding at the CYP3A4 promoter. These passages support transcriptional induction in the cell model studied. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2.2. Taxonomy of Berberine’s Interaction Mechanisms · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Concurrent, often undisclosed use with prescription drugs is common in older adults, yet berberine is far from inert.”
- Also stated in: § 1. Introduction · plain
“Population studies report that between 5% and over 80% of older adults combine supplements with prescription drugs, and a substantial proportion carry at least one potential interaction [3,4,5,6,7].”
§ Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification—A Narrative Review > Abstract
What the sources say
- Partly supportedcites [3] Agbabiaka T.B. Spencer N.H. Khanom S. Goodman C. Prevalence of drug-herb and drug-supplement interactions in older adults: A cross-sectional survey Br. J. Gen. Pract. 2018 68 e711 e717 10.3399/bjgp18X699101 30249608 PMC6145997 sourceExperimental — accuracy not yet measured
The Results (‘Prevalence and pattern of concurrent use’) report that 33.6% of surveyed older adults used herbal products or supplements with prescription drugs. The Discussion (‘Comparison with existing literature’) says some patients may not disclose such use, even when questioned. Neither passage establishes that berberine use specifically is common or often undisclosed. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [4] Loya A.M. González-Stuart A. Rivera J.O. Prevalence of polypharmacy, polyherbacy, nutritional supplement use and potential product interactions among older adults living on the United States-Mexico border: A descriptive, questionnaire-based study Drugs Aging 2009 26 423 436 10.2165/00002512-200926050-00006 19552494 source
- Partly supportedcites [5] Agbabiaka T.B. Wider B. Watson L.K. Goodman C. Concurrent Use of Prescription Drugs and Herbal Medicinal Products in Older Adults: A Systematic Review Drugs Aging 2017 34 891 905 10.1007/s40266-017-0501-7 29196903 PMC5730633 sourceExperimental — accuracy not yet measured
The Discussion’s Implications for Practice section says that many older adults use herbal medicinal products alongside prescription drugs and that most do not disclose this to healthcare practitioners. The review does not establish that concurrent, undisclosed use of berberine specifically is common; its findings concern herbal products as a group. (LLM, conf=0.87)
- Partly supportedcites [6] Changaramkumarath G. Abucha J.M. Wollel M.M. Somannagari N. Kasagga A. Sapkota A. Malasevskaia I.A. Pharmacological Interactions Between Nutritional Supplements and Prescription Medications in Older Adults: A Comprehensive Review Cureus 2025 17 e92363 10.7759/cureus.92363 41103884 PMC12526737 sourceExperimental — accuracy not yet measured
The Review (page not available) reports that older adults commonly use supplements alongside prescription drugs and frequently fail to report supplement use to doctors. It does not identify berberine or establish that concurrent, undisclosed use of berberine specifically is common. (LLM, conf=0.88)
- Partly supportedcites [7] Djuv A. Nilsen O.G. Steinsbekk A. The co-use of conventional drugs and herbs among patients in Norwegian general practice: A cross-sectional study BMC Complement. Altern. Med. 2013 13 295 10.1186/1472-6882-13-295 24171723 PMC4228482 sourceExperimental — accuracy not yet measured
The Abstract Results and Discussion (Characteristics of co-users) report frequent herb–drug co-use, with higher co-use among patients over 70. The Results also report that nearly 80% of herb users did not discuss their use with a health professional. These findings concern herbs generally; the paper does not establish that berberine co-use is common or often undisclosed among older adults. (LLM, conf=0.88)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 1. Introduction · plain
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The failure of patient–clinician communication about supplement use amplifies this risk, as physicians rarely initiate the discussion [1,3].”
§ Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification—A Narrative Review > 1. Introduction
What the sources say
- Partly supportedcites [1] Tachjian A. Maria V. Jahangir A. Use of herbal products and potential interactions in patients with cardiovascular diseases J. Am. Coll. Cardiol. 2010 55 515 525 10.1016/j.jacc.2009.07.074 20152556 PMC2831618 sourceExperimental — accuracy not yet measured
The Introduction says physicians may not routinely ask about complementary and alternative medicine use and that dangerous herb–drug interactions may consequently be missed. This supports the communication-and-risk point, but the claim’s unqualified “rarely initiate” is stronger than the paper’s hedged wording. (LLM, conf=0.82)
- Partly supportedcites [3] Agbabiaka T.B. Spencer N.H. Khanom S. Goodman C. Prevalence of drug-herb and drug-supplement interactions in older adults: A cross-sectional survey Br. J. Gen. Pract. 2018 68 e711 e717 10.3399/bjgp18X699101 30249608 PMC6145997 sourceExperimental — accuracy not yet measured
The Discussion (Comparison with existing literature; Implications for practice, page unavailable) says patients may not disclose supplements even when questioned and recommends direct questioning to identify potential interactions. It does not establish that physicians rarely initiate these discussions or measure how often they do so. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
51 more claims · 33 with their cited sources checked
Create a free account to see all 159 claims and to verify the 3 references still open.
- It may state two separate claims as one. 95
- Probably not a substantial claim. 22
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification—A Narrative Review > 2. Results and Discussion > 2.3. Victim Drugs and the Strength of the Evidence for Each Pair
“A separate study in healthy volunteers confirmed the direction of the interaction [117].”
§ Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification—A Narrative Review > 2. Results and Discussion > 2.6. Limitations of the Review
“Across the whole field we identified one controlled study in patients, in renal-transplant recipients receiving cyclosporine, one probe-cocktail study in healthy volunteers, and one human enzyme-phenotyping study; everything else is preclinical, in vitro or observational.”
Citations
Cites
Munn, Z., Peters, M. D. J., Stern, C., Tufanaru, C., McArthur, A., & Aromataris, E. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0611-x · Cited by 11,385 · cited 5×
“…approach is justified by the methodological heterogeneity of the evidence, which brings together in vitro mechanistic studies, preclinical models, clinical pharmacokinetic and pharmacodynamic studies, case reports, and regulatory documents that are difficult to aggregate quantitatively [125].”
InfluentialINFOGEST static in vitro simulation of gastrointestinal food digestion
Brodkorb, A., Egger, L., Alminger, M., Alvito, P., Assunção, R., Ballance, S., Bohn, T., Bourlieu-Lacanal, C., Boutrou, R., Carrière, F., et al. (2019) · Nature Protocols · doi:10.1038/s41596-018-0119-1 · Cited by 5,199
SANRA—a scale for the quality assessment of narrative review articles
Baethge, C., Goldbeck-Wood, S., & Mertens, S. (2019) · Research Integrity and Peer Review · doi:10.1186/s41073-019-0064-8 · Cited by 3,469 · cited 2×
“This work is designed as a structured narrative review, with transparent reporting of the documentation strategy, guided by the quality criteria of the Scale for the Assessment of Narrative Review Articles (SANRA) [124].”
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965 · cited 5×
“This places berberine within the broader group of drugs and supplements with a risk of induced arrhythmia, moni-torable through pharmacovigilance, in which the pharmacist’s assessment has a preventive role [91,93,94].”
InfluentialKong, W., Wei, J., Abidi, P., Lin, M., Inaba, S., Li, C., Wang, Y., Wang, Z., Si, S., Pan, H., et al. (2004) · Nature Medicine · doi:10.1038/nm1135 · Cited by 1,391 · cited 1×
“…it is supported by a consistent body of evidence for hypoglycemic and lipid-lowering effects, mediated through multiple mechanisms: activation of AMP-activated protein kinase (AMPK) [18–21], increased insulin-receptor expression [22], reduction in PCSK9 [23] and regulation of non-coding RNAs [24].”
Mapping human microbiome drug metabolism by gut bacteria and their genes
Zimmermann, M., Zimmermann-Kogadeeva, M., Wegmann, R., & Goodman, A. L. (2019) · Nature · doi:10.1038/s41586-019-1291-3 · Cited by 1,160 · cited 3×
“The relevance to interactions arises from the fact that the microbiome is a general mediator of xenobiotic metabolism, capable of activating, inactivating or recycling numerous drugs [103–105].”
Lee, Y. S., Kim, W. S., Kim, K. H., Yoon, M. J., Cho, H. J., Shen, Y., Ye, J.-M., Lee, C. H., Oh, W. K., Kim, C. T., et al. (2006) · Diabetes · doi:10.2337/db06-0006 · Cited by 1,054
Efficacy of berberine in patients with type 2 diabetes mellitus
Yin, J., Xing, H., & Ye, J. (2008) · Metabolism · doi:10.1016/j.metabol.2008.01.013 · Cited by 801 · cited 5×
“…risk via [30,65] B and C—clinical probe-cocktail study plus in vivo preclinical [65,82,83] Sulfonylureas, insulin Pharmacodynamic additivity [38] ↑ hypoglycemia risk [30] B—clinical, pharmacodynamic endpoint [30,38] GLP-1 receptor agonists Additivity (glycemia, gastric emptying) [47] ↑…”
InfluentialThe microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717 · cited 2×
“What would settle the question is a study measuring the pharmacokinetics of a microbiota-dependent victim drug before and after berberine, with the microbiota characterized in the same subjects; we set this out in Section 2.5 [104–106].”
Influential
Cited by
Alanazi, S. M., Al‐kuraishy, H. M., Abdelaziz, A. M., Alasmari, E. M., Yousef, F. M., Mohamed, A. A., Salama, M. M., & Batiha, G. E. (2026) · Fitoterapia · doi:10.1016/j.fitote.2026.107497
Metadata
- Authors
- Dumitru, C. N., Marcu, T., Dumitru, A. O., Tudor, S. S., Ferțu, I. D., Elisei, A.-M., & Goroftei, L.
- Affiliations
- "Dunarea de Jos" University of Galati (RO)
- Research Centre in the Medical-Pharmaceutical Field, Faculty of Medicine and Pharmacy, “Dunărea de Jos” University of Galați, 35 Al. I. Cuza Street, 800010 Galați, Romania
- Corresponding author
- Dumitru, Alina Oana
- ORCID
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2026-08-20
- Volume
- 19
- Issue
- 8
- Pages
- 1313
- ISSN
- 1424-8247 (ISSN-L)
- PMC
- PMC13516377
- OpenAlex
- W7203828452
- Cited by
- 2
- References
- 115
- Citations by year
- 2026: 2
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceuticals (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Berberine and alkaloids research
- Health Sciences › Medicine › Complementary and alternative medicine › Complementary and Alternative Medicine Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- berberine, drug-supplement interactions, drug interactions, CYP3A4 inhibition, CYP2D6 inhibition, CYP2C9 inhibition, P-glycoprotein, MATE1, cyclosporine, kidney transplant recipients, QT prolongation, hypoglycemia, hypotension, gut microbiota, intestinal barrier, risk stratification, medication reconciliation, older adults, herbal supplements, regulatory limits, narrow therapeutic index
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.